Title: A Novel Broad-Spectrum Solid Tumor Treatment Hypothesis via Metabolic Intervention Synergizing with Hyperbaric Oxygen and Immune Surveillance Networks: Targeting the Warburg Effect Vulnerability

This paper proposes a comprehensive two-stage anti-cancer hypothesis. In the first  stage,  we  combine   Pyrroloquinoline   quinone  (PQQ),  Coenzyme  Q10 (CoQ10),  Astragalus  Polysaccharide  (APS),  and  an  Nicotinamide  adenine dinucleotide (NAD)+ supplement.  Based on the characteristic  mitochondrial functional  defects  of  cancer  cells,  this  combination  selectively  accumulates within them: PQQ and CoQ10 become a metabolic burden due to ineffective utilization,  while   APS  and  NAD+  further  enhance  glycolytic  metabolism, collectively pushing cancer cells into a high reductive stress state. Cells in this state  become  extremely  sensitive  to  subsequent  Hyperbaric  Oxygen  (HBO)
therapy, which triggers a catastrophic  intracellular  Reactive  Oxygen  Species (ROS) burst and death. Survivors, having activated the Nuclear factor erythroid 2-related factor 2 (NRF2) antioxidant program, upregulate Heme Oxygenase-1 (HO-1), causing a transient surge in intracellular free iron. Timely application of an  NRF2  activator  then  expands the  iron  pool,  exploiting  the  delayed  iron

export  window  to   induce   Ferroptosis.   Crucially,   the   same   combination enhances mitochondrial biogenesis and antioxidant defenses in normal cells, thereby protecting them. In the second stage, the metabolic intervention clears systemic   lactate,   reverses   tumor    microenvironment   immunosuppression, polarizes macrophages towards the M1 phenotype, and forces residual cancer cells to switch to Oxidative  Phosphorylation  (OXPHOS),  upregulating  Major Histocompatibility Complex class  I  (MHC-I) and CD1d antigen  presentation.
This  renders  them  susceptible  to  complete  eradication  by  a  multi-layered immune  surveillance  network comprising  CD8⁺  T  cells,  Natural  Killer  (NK)
cells,  CD4⁺  T  cells,  and  invariant  Natural  Killer  T  (iNKT)  cells capable  of circumventing  immune  checkpoints.  This  hypothesis  provides  a  theoretical framework for a systemic solid tumor treatment that is theoretically on-target, low-toxicity, and capable of overcoming resistance.